{"entity":{"id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","aka":[],"tldr":"A phase 2/3 trial of Adebrelimab and SHR-A2102 in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) is a phase 2/3 interventional study registered as NCT06879145 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 840 participants planned, started 2025-04-25 and due to reach its primary completion in 2031-12. Interventions recorded: SHR-A2102；Adebrelimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06879145","url":"https://clinicaltrials.gov/study/NCT06879145"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["adebrelimab","shr-a2102"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06879145","phase":"2/3","setting":"A Randomized, Open, Multicenter Phase II/III Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":840,"outcomes":[]},"route":"/trials/nct06879145/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}